Member Info for Nolupus

I agree with your point of view that the LT holders have been badly done by ..

I just hope some white knight will come out of the blue

Oscar,

Whilst the reply from IMM seems logical , it also raises questions on the proactive nature of the relationship between Avion and IMM .imo
One must presume that the response from the FDA is not just a yes or a no , to proceed with a P3 trial, otherwise they wouldn’t need time to discuss things that have already been discussed, would they ?

L1 and Lind are Finance companies so they are only interested in making money quickly ..Quick Profit is the name of their game so one cannot read more than that into their conversions , imo

Bottom feeder,

Lind and L1 capital are not classed as ´ insiders ´
They have no directors on the BOD so they have no ´direct access to price sensitive information

The company must inform the market in a reasonable timely manner on any major news that would affect the company.

Patience as we know is a virtue , and Imm shareholders are very virtuous :-)

Hi Trek,

All well apart from the biotech valuations :-)

IQAI should not be promoting ´ commentary from participants in an ongoing clinical trial , full stop .

Sponsors should have a minimum ethical conduct even though individuals have Facebook etc etc , so snippets will come out but IQAI should not be promoting this !

It’s the first time I have seen the FDA asking for a PK study to give the go ahead for a P3 clinical trial ..

The explanation is , imo again contained in the brief paragraph of the RNS …see below …Lupuzor update

As part of the regulatory process, the Investigational Medicinal Product Dossier ("IMPD") required significant revision, due to the inclusion of a new proprietary synthesis of P140, which consequently affords greater IP protection and lower cost of goods.

Normally , the sponsor of a clinical trial would/ should not communicate like this

Maestro ,

Why do you think the FDA asked for the PK which is usually a P1 trial ?
But
I agree wholeheartedly that even preclinical not to mind P2 assets are sometimes valued at 100’s of millions .
Welcome to the biotech world !

Lambo222,

90% drop is not conceivable as the worst case scenario, IMO , is that the FDA demand a P2 trial but everyone to their own opinions .
Everyone should calculate the odds and be prepared for a major move .. Up or down

Whatever will be will be

The link is as follows …

https://www.lse.co.uk/rns/IMM/lupuzor-update-q1rdbjyj9nbs9kx.html

Lambo222,

As you seem too busy ( buying ? ) I will share the info ..

The paragraph from the RNS stated

As part of the regulatory process, the Investigational Medicinal Product Dossier ("IMPD") required significant revision, due to the inclusion of a new proprietary synthesis of P140, which consequently affords greater IP protection and lower cost of goods. The new IMPD was submitted to the MHRA and, following a full review, the MHRA has approved the commencement of the PK study.

Next , Lambo222 ?? :-)

They hve changed the Drug, and updated the formulation that’s the gamble here with the FDA as if they said Lupozor needed to start a phase 1 and phase 2 trial all over again …

Lambo222,
I wonder where you got that idea from ?

Some stop losses might have been triggered…

Let’s see

The acquisition takes Mr Cerrone's interests from 37.61% to 37.70%.

He certainly is confident

Very strange behavior / volatility

Would’nt be surprised to see it move up from here but wtfdik

They can’t sell anything until they get their hands on the converted shares which are due for admission on the 30th , or can they ?

BTW

It’s L1 capital that has converted today and not LIND but whatever..

They have options over 7-8% of the company as do Lind also ..

Cuvio,

Your thoughts are in accordance with my own but they are not in the same position as most holders ..
They can sit back and wait for some real movement in the Sp before converting .
To be perfectly clear , I am surprised they have converted NOW and for so little